BioSpace News Archive

Increasing occurrences of chronic diseases is one of the significant factors influencing market growth.

Scorpion Therapeutics, Inc., a next-generation oncology company developing best- and first-in-class precision medicines for cancer patients, today announced that Dr. Axel Hoos will join the Company as its new Chief Executive Officer, effective August 2021

Eyenovia, Inc., a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print platform technology, announced that management will present a corporate overview and host one-one-one meetings at the Ladenburg Thalmann 2021 Healthcare Conference, being held virtually July 13-14, 2021, and host one-on-meetings at the William Blair Biotech Focus Conference 2021, being held virtually July 14-15, 2021.

10x Genomics announced it will report financial results for the second quarter 2021 after market close on Wednesday, August 4th, 2021.

Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced it earned a significant milestone payment related to the licensing of its proprietary CodeEvolver® protein engineering platform technology to GlaxoSmithKline (GSK).

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2021 before the market opens on Wednesday, July 28, 2021, and will hold a conference call on the same day at 8:30 a.m. EDT.

Blueprint Medicines Corporation announced that, effective on July 1, 2021, the Compensation Committee of Blueprint Medicines’ Board of Directors granted non-qualified stock options to purchase an aggregate of 25,762 shares of its common stock and an aggregate of 12,880 restricted stock units to 12 new employees under Blueprint Medicines’ 2020 Inducement Plan.

BioSig Technologies, Inc. announced the completion of its previously announced underwritten public offering of 2,500,000 shares of its common stock, $0.001 par value per share, at a price to the public of $4.00 per share.

Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a panel discussion, Moving Beyond Monoclonals: The Potential of Multispecific Therapies, at William Blair’s Biotech Focus Conference 2021 on Wednesday, July 14 at 11:20 a.m. ET.

IDEAYA Biosciences, Inc. announced the pricing of an underwritten public offering of 4,637,681 shares of its common stock at a public offering price of $17.25 per share, before underwriting discounts and commissions.